On July 13, 2026, treatment for early Alzheimer's changed: eligible people can now start Leqembi at home with a weekly injection. The IV infusion option remains, and eligibility and safety monitoring did not change.
Leqembi is a drug that targets amyloid, a protein that builds up in the brains of people with Alzheimer's disease. Early Alzheimer's here means mild cognitive impairment or mild dementia due to Alzheimer's, with amyloid confirmed by testing. Eisai reported the home-start approval in its approval announcement Eisai approval announcement.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Official resources:
- Check eligibility on Biospace’s official study page — Use this page to check the study’s participation requirements.
- Apply through Eisai’s official page — Use this page to review requirements and apply directly.
Table of Contents
- What the 2026 decision changed
- How home dosing compares with IV infusions
- Who qualifies under the new approval
- What safety checks stay the same
- What to ask before choosing a route
What the 2026 decision changed
Before this decision, the subcutaneous form could be used only for maintenance after 18 months of IV therapy. That meant every patient had to start with regular trips to an infusion center.
The 2026 approval allows treatment to begin at home with LEQEMBI IQLIK, once-weekly lecanemab-irmb given under the skin. Medscape noted that this step removed the infusion-center requirement for starting therapy Medscape analysis.
How home dosing compares with IV infusions
The home initiation dose is 500 mg each week, given as two 250-mg autoinjector injections. Maintenance is 360 mg each week. The IV dose remains 10 mg per kilogram every two weeks.
Patients can use either route from initiation through maintenance. They can also switch routes in either direction for flexibility. Practical differences include:.
- home shots avoid IV placement, infusion time, and biweekly clinic travel
- home shots require proper storage, handling, and injection technique
- clinic infusions keep dosing and observation in the hands of staff
Who qualifies under the new approval
Eligibility did not expand with the new route. Treatment is only for adults with mild cognitive impairment or mild dementia due to Alzheimer's, collectively called early Alzheimer's, with confirmed amyloid pathology. The press release carried by BioSpace states that same eligibility standard BioSpace press release. People with more advanced dementia do not qualify.
People without confirmed amyloid do not qualify. A diagnosis alone is not enough. Families will still need memory testing, a clinician assessment, and amyloid testing. Ask the dementia clinic which amyloid test it accepts before scheduling.
What safety checks stay the same
Home dosing does not mean home alone. MRI monitoring for amyloid-related imaging abnormalities, called ARIA, remains required. Caregiver training and clinician oversight remain required regardless of route. ARIA can cause headache, confusion, dizziness, vision changes, or no symptoms at all.
The drug carries a boxed warning for ARIA. Counseling about ApoE-e4 gene-related risk also continues. Practical rollout runs through specialty pharmacy. Eisai launched the initiation dose in the United States in late August 2026 through that channel. Keep all MRI appointments, report new neurologic symptoms promptly, and confirm who to call after hours.
What to ask before choosing a route
Start with logistics and support at home. Can the patient and caregiver store the drug, give two injections each week, and track doses? Is help available if a dose is missed or partly injected? Then weigh medical fit and preference.
Needle comfort, skin reactions, travel distance to infusion, work schedules, and other health issues matter. Review MRI timing, ARIA symptoms, and ApoE-e4 testing with the prescribing clinician, then choose the route the household can follow consistently.
You Might Also Like
- Why the AAIC 2026 Soccer Study Does Not Prove Dementia: What Researchers Still Need to Learn for People With Mild Cognitive Impairment
- Safety Questions After the 2026 LiBBY Dementia Trial: What Researchers Still Need to Learn for People With Mild Cognitive Impairment
- AAIC 2026 p-tau217 Alzheimer’s Risk Prediction Research: Who Was Studied and Who Was Not for People With Mild Cognitive Impairment
